FDA Fast-Tracks Singapore Blood Test for 10 Cancers

Getting screened for cancer could soon become as simple as a routine blood draw, thanks to a Singapore company that just earned a major vote of confidence from American regulators.

The U.S. Food and Drug Administration granted Breakthrough Device Designation to SPOT-MAS 10, a blood test developed by Gene Solutions that can detect signals from 10 different cancers. This special status means the FDA recognizes the test's potential to save lives and will work closely with the company to bring it to American patients.

The test works by analyzing DNA fragments floating in the blood, looking for patterns that indicate cancer might be present. It targets breast, lung, liver, colorectal, gastric, ovarian, pancreatic, esophageal, endometrial, and head and neck cancers in adults 40 and older who have no symptoms.

What makes this particularly exciting is that many of these cancers lack good early screening options. While mammograms catch breast cancer and colonoscopies find colon cancer, tests for pancreatic or ovarian cancer remain limited. SPOT-MAS 10 could fill those gaps.

The test isn't just theoretical. More than 100,000 people across Asia have already used it in real-world settings. A major study published in BMC Medicine last year followed over 9,000 healthy participants and found the test performed well, accurately flagging cancer signals while avoiding false alarms.

Gene Solutions plans to launch in the United States by late 2026. The company emphasizes that SPOT-MAS 10 won't replace existing cancer screenings like mammograms or colonoscopies but will work alongside them, catching cancers that might otherwise go undetected until symptoms appear.

The Ripple Effect

Early cancer detection dramatically improves survival rates. When caught early, many cancers that would be fatal at later stages become highly treatable. A blood test that screens for multiple cancers at once could transform routine checkups, potentially catching tumors years before they cause symptoms.

The technology combines three types of DNA analysis with machine learning to spot subtle patterns that indicate cancer. This multi-layered approach helps the test maintain high accuracy, a critical requirement for any screening tool used on healthy people.

Gene Solutions CEO Dr. Nguyen Hoai Nghia calls the FDA designation "a defining milestone" that validates years of research. The company continues working with doctors and regulators worldwide to gather evidence supporting the test's responsible use in cancer screening programs.

For millions of people who face cancers with limited early detection options, this blood test represents genuine hope.